// App-Quantinova.ai

: Efficacy and Safety of E7777 (improved purity Denileukin diftitox [ONTAK]) in Patients with Relapsed or Refractory Cutaneous T-Cell Lymphoma: Results from Pivotal Study 302

Researchers

Presenter

  • Francine M. Foss

Principal Investigators

  • Youn H. Kim

  • H. Miles Miles Prince

  • Timothy M. Kuzel

  • Costas K. Yannakou

  • Chean Eng Ooi

  • Dongyuan Xing

  • Nicholas Sauter

  • Preeti Singh

  • Myron Czuczman

  • Madeleine Duvic

Medical Centers

  • Peter MacCallum Cancer Centre, MELBOURNE, Australia

  • Department of Dermatology, Stanford University School of Medicine, Palo Alto, CA

  • Peter MacCallum Cancer Inst., East Melbourne, AUS

  • Epworth Healthcare, Melbourne, Australia

  • Stanford Cancer Institute/Cutaneous Lymphoma, Stanford University School of Medicine, Palo Alto, CA

  • Yale University School of Medicine, New Haven, CT

  • The University of Texas M.D. Anderson Cancer Center, Houston, TX

  • Department of Internal Medicine, Section of Hematology, Yale University School of Medicine, New Haven, CT

  • Yale Cancer Center and Yale School of Medicine, New Haven, CT

  • Rush University Cancer Center, Rush University Medical Center, Chicago, IL

  • MD ANDERSON CANCER CENTER, HOUSTON, TX

Locations

  • Australia

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Cutaneous T-cell lymphoma

Biomarkers

  • Transthyretin

  • ZFP36 Ring Finger Protein Like 1

Drug/Treatment

  • E7272

Outcome

  • N/A

Study Design

  • Efficacy

  • Safety

  • Open Label

  • Single Arm

  • Multicenteric

  • Tolerability

  • Immunogenicity

  • Global

  • pivotal

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved